Two US scientists awarded Balzan Prize for cancer research

September 11, 2017 by Colleen Barry
Salvatore Veca attends a press conference to present a 2017 Balzan's prize edition, in Milan, Italy, Monday, Sept. 11, 2017. James Allison of the University of Texas MD Anderson Cancer Center and Robert Schreiber of the Washington School of Medicine were announced Monday as winners of the 750,000 Swiss franc (660,000 euro, $790,000) prize. They were cited for work that has helped use antibody treatments that has increased the survival of patients with metastic melanoma. (AP Photo/Antonio Calanni)

Two U.S. scientists whose work has contributed to creating immunological treatments for cancer are among the winners of this year's Balzan Prizes, announced Monday, recognizing scholarly and scientific achievements.

James Allison of the University of Texas MD Anderson Cancer Center and Robert Schreiber of the Washington University School of Medicine were cited for their work on antibody treatments that has increased the survival of patients with metastatic melanoma.

The Balzan Foundation awards two prizes in the sciences and two in the humanities each year, rotating specialties to highlight new or emerging areas of research and sustain fields that might be overlooked elsewhere. Recipients receive 750,000 Swiss francs ($790,000), half of which must be used for research, preferably by young scholars or scientists.

Nobel Prize-winner Jules Hoffman, a presenter of the awards, said the work focusing on using the immune system to fight cancer, expanding from the traditional treatments of removal, radiation and chemotherapy, has already had success in 25 to 30 percent of melanoma patients in a study who had previously gone through the traditional battery of treatments. It is now being developed for small cell lung cancer and rectal cancer.

Other winners are:

—Belgian astrophysicist Michael Gillon for his work that has helped map new solar systems from the comfort of planet Earth, using robotic telescopes instead of much more costly satellites.

Thomas Maissen speaks to journalists during a press conference to present a 2017 Balzan's prize edition, in Milan, Italy, Monday, Sept. 11, 2017. James Allison of the University of Texas MD Anderson Cancer Center and Robert Schreiber of the Washington School of Medicine were announced Monday as winners of the 750,000 Swiss franc (660,000 euro, $790,000) prize. They were cited for work that has helped use antibody treatments that has increased the survival of patients with metastic melanoma. (AP Photo/Antonio Calanni)

—Germans Aleida and Jan Assmann, a married couple recognized for their work presenting collective memory "as a requirement for the formation of the identity of religious and political communities."

—Indian economist Bina Agarwal, a professor at the University of Manchester, recognized in the gender studies category for her "heroic" work studying women's contributions to agriculture in India.

—This year, the Balzan Foundation also awarded a fifth prize, in international relations, which was deferred from last year after the committee failed to reach agreement on a winner. It went to Robert O. Keohane of the Woodrow Wilson School at Princeton University, best known for his influential 1984 book "After Hegemony: Cooperation and Discord in the World Political Economy."

Prizes will be awarded in Bern, Switzerland, on Nov. 17.

Explore further: 1 Japanese, 2 Americans win Crafoord science prize

Related Stories

1 Japanese, 2 Americans win Crafoord science prize

January 12, 2017
A Japanese and two American scientists have been awarded the 2017 Crafoord Prize for fundamental discoveries in immune regulation.

Recommended for you

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Without 'yoga and chardonnay' leukemia stem cells are stressed to death

June 14, 2018
Change is stressful. The change that a healthy blood stem cell undergoes to become a leukemia stem cell (LSC) is no exception—think of healthy blood stem cells as young professionals and the transformation into an LSC as ...

Statins found to enhance efficacy of chemotherapy drug in blood cancers

June 14, 2018
A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance the efficacy of a chemotherapy drug used to fight blood cancers in mouse models. In their paper ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.